{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:58:02Z","timestamp":1791331082193,"version":"4.3.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ijrobp.2008.08.050","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T14:13:02Z","timestamp":1229004782000},"page":"433-439","source":"Crossref","is-referenced-by-count":78,"title":["Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies"],"prefix":"10.1016","volume":"74","author":[{"given":"Gregory J.","family":"Kubicek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Werner-Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Machtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Walter J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2008.08.050_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","article-title":"Brain tumors","volume":"344","author":"DeAngelis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib3","first-page":"121","article-title":"Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma","volume":"67","author":"Green","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1989.71.1.0001","article-title":"Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group trial 8001","volume":"71","author":"Shapiro","year":"1989","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib6","article-title":"Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib8","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"for the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib9","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/01243894-200611000-00013","article-title":"Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial (S0327)","volume":"9","author":"Lara","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib11","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non\u2013small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01243894-200602000-00005","article-title":"Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: A phase I California Cancer Consortium trial","volume":"1","author":"Lara","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-06-2046","article-title":"Phase I\/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer","volume":"13","author":"Dreicer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib14","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.22280","article-title":"A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors","volume":"107","author":"Ryan","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/annonc\/mdj131","article-title":"Bortezomib (VELCADE\u00ae) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits","volume":"17","author":"Yang","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib16","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1158\/1078-0432.CCR-07-0251","article-title":"Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"13","author":"Koschny","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib17","first-page":"4499","article-title":"Activity of bortezomib in glioblastoma","volume":"26","author":"Styczynski","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/labinvest.3700123","article-title":"Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas","volume":"84","author":"Wang","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib19","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-03-0392","article-title":"In vitro and in vivo activity of the nuclear factor-B inhibitor sulfasalazine in human glioblastomas","volume":"10","author":"Robe","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 7","key":"10.1016\/j.ijrobp.2008.08.050_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdl963","article-title":"Apoptosis: a relevant tool for anticancer therapy","volume":"17","author":"Russo","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib21","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/0008-5472.CAN-04-0673","article-title":"Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implications for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma","volume":"64","author":"Amiri","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib22","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","article-title":"Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials","volume":"25","author":"Carson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.08.050_bib23","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive portioning analysis of the EORTC 26981\/22981\u2013NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301608035128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301608035128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T05:08:09Z","timestamp":1557983289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301608035128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0360301608035128"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.050","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}